文献类型：期刊文献

英文题名：Anti-hypertensive and gut microbiota regulatory effects of yeast protein hydrolysate on spontaneous hypertensive rat

作者：Wang, Yijia[1,2];Xie, Dewei[1,2];Zhao, Li[1,2];Chen, Zhixian[2,3,4];Zhang, Yan[3,4,5];Du, Lei[1,2,7];Xie, Jingli[1,2,6,7]

机构：[1]State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China;[2]East China Univ Sci & Technol, Sch Biotechnol, Dept Food Sci & Engn, Shanghai 200237, Peoples R China;[3]Natl Key Lab Agr Microbiol, Yichang 443003, Peoples R China;[4]Hubei Prov Key Lab Yeast Funct, Yichang 443003, Peoples R China;[5]Yichang Engn Technol Res Ctr Nutr & Hlth Food, Yichang 443003, Peoples R China;[6]Shanghai Collaborat Innovat Ctr Biomfg SCICB, Shanghai 200237, Peoples R China;[7]East China Univ Sci & Technol, POB 283,130 Meilong Rd, Shanghai 200237, Peoples R China

年份：2024

卷号：140

起止页码：66

外文期刊名：PROCESS BIOCHEMISTRY

收录：;EI(收录号：20241015706095);WOS:【SCI-EXPANDED(收录号:WOS:001202514700001)】；

基金：This work was supported by National Key Research and Development Program of China (No. 2020YFA0907800; No. 2021YFC2100300) ; Natural Science Foundation of Shanghai (No. 21ZR1416200) ; Guangdong Provincial Key Laboratory of Aquatic Product Processing and Safety (No. GDPKLAPPS2001), China.

语种：英文

外文关键词：Yeast protein hydrolysate; Antihypertension; Angiotensin converting enzyme; Oxidative stress; Gut microbiota

摘要：This study aims to evaluate the in vivo anti-hypertensive activity and the intestinal microbiota regulation of yeast protein hydrolysate (YH) on spontaneous hypertensive rat (SHR). The YH was produced by alkali protease hydrolysis and ultrafiltration, with the ACE inhibitory IC50 of 0.11 mg/mL. Treatment with 200 mg/kg BW and 400 mg/kg BW of YH resulted in 12 and 17 mmHg of decrease in systolic blood pressure (SBP), respectively, at 4 h after the first administration. For 4-week administration, both dosages of the YH could decrease about 20 mmHg of SBP compared with untreated SHRs. The YH modulated blood pressure by inhibiting serum ACE activity, lowering Ang II content, and upregulating the expression of AT2R at the higher dose. The YH also alleviated oxidative stress in SHRs, significantly elevating serum GSH (24%) and reducing MDA content (50%). In addition, the YH could restore the gut microbiota dysbiosis of SHR, and increased the titer of fecal short-chain fatty acids (SCFAs) as well as the relative abundance of SCFA producing bacteria, including Roseburia, Bacteroides, Ruminococcaceae_UCG-005, Ruminococcaceae_UCG-014 and Alloprevotella. According to the correlation analysis, significant relevances among blood pressure, serum ACE activity, Ang II level, oxidative stress, fecal SCFAs, and gut microbiota in SHR were found. Therefore, YH is a promising functional component in lowering blood pressure and regulating intestinal microbiota.